Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5855-5864

  Servettaz, Amélie ^a,c   Goulvestre, Claire ^a   Kavian, Niloufar ^a   Nicco, Carole ^a   Guilpain, Philippe ^a,b   Chéreau, Christiane ^a   Vuiblet, Vincent ^d   Guillevin, Loïc ^b   Mouthon, Luc ^a,b   Weill, Bernard ^a   Batteux, Frédéric ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Hôpital Cochin ^*  (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d HÔPITAL MAISON BLANCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; BLEOMYCIN; CENTROMERE PROTEIN B; DNA TOPOISOMERASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; HYPOCHLORITE; HYPOCHLOROUS ACID; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME METABOLISM; FEMALE; HUMAN; HUMAN CELL; LUNG FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCID MOUSE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL LINE; CELL STRAIN 3T3; DBA MOUSE; DISEASE MODEL; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NEW ZEALAND BLACK MOUSE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, INBRED NZB; MICE, SCID; NIH 3T3 CELLS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PULMONARY FIBROSIS; REACTIVE OXYGEN SPECIES; SCLERODERMA, SYSTEMIC;

EID: 66949168883     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803705     Document Type: Article

References (45)

1. LeRoy, E. C., and T. A. J. Medsger. 2001. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28: 1573-1576. (Pubitemid 32660630)
2. Herrick, A. L., and A. Worthington. 2002. Genetic epidemiology: systemic sclerosis. Arthritis Res. 4: 165-168.
3. Gabrielli, A., S. Svegliati, G. Moroncini, G. Pomponio, M. Santillo, and E. Avvedimento. 2008. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin. Immunopathol. 30: 329-337.
4. Simonini, G., M. Matucci Cerinic, S. Generini, M. Zoppi, M. Anichini, C. Cesaretti, A. Pignone, F. Falcini, T. Lotti, and M. Cagnoni. 1999. Oxidative stress in Systemic Sclerosis. Mol. Cell Biochem. 196: 85-91.
5. Herrick, A. L., and M. Matucci Cerinic. 2001. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin. Exp. Rheumatol. 19: 4-8.
6. Servettaz, A., P. Guilpain, C. Goulvestre, C. Chéreau, C. Hercend, C. Nicco, L. Guillevin, B. Weill, L. Mouthon, and F. Batteux. 2007. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann. Rheum. Dis. 66: 1202-1209. (Pubitemid 47309738)
7. Sambo, P., S. S. Baroni, M. Luchetti, P. Paroncini, S. Dusi, G. Orlandini, and A. Gabrielli. 2001. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 44: 2653-2664. (Pubitemid 33049343)
8. Ogawa, F., K. Shimizu, E. Muroi, T. Hara, M. Hasegawa, K. Takehara, and S. Sato. 2006. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 45: 815-818. (Pubitemid 43985368)
9. Allanore, Y., D. Borderie, H. Lemarechal, O. G. Ekindjian, and A. Kahan. 2004. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am. J. Med. 116: 595-600. (Pubitemid 38490533)
10. Sambo, P., L. Jannino, M. Candela, A. Salvi, M. Donini, S. Dusi, M. M. Luchetti, and A. Gabrielli. 1999. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J. Invest. Dermatol. 112: 78-84. (Pubitemid 29024710)
11. Baroni, S. S., M. Santillo, F. Bevilacqua, M. Luchetti, T. Spadoni, M. Mancini, P. Fraticelli, P. Sambo, A. Funaro, A. Kazlauskas, et al. 2006. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N. Engl. J. Med. 354: 2667-2676. (Pubitemid 43920840)
12. Black, C., S. Pereira, A. McWhirter, K. Welsh, and R. Laurent. 1986. Genetic susceptibility to scleroderma-like syndrome in symptomatic and asymptomatic workers exposed to vinyl chloride. J. Rheumatol. 13: 1059-1062. (Pubitemid 17027657)
13. Tamby, M. C., M. Humbert, P. Guilpain, A. Servettaz, N. Dupin, J. J. Christner, G. Simonneau, J. Fermanian, B. Weill, L. Guillevin, and L. Mouthon. 2006. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur. Respir. J. 28: 799-807. (Pubitemid 46332002)
14. Masi, A. T., G. P. Rodnan, T. A. Medsger, R. D. Altman, W. A. D'Angelo, and J. F. Fries. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma): Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581-590.
15. LeRoy, E. C., C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T. A. J. Medsger, N. Rowell, and F. Wollheim. 1988. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15: 202-205. (Pubitemid 18073738)
16. Dalle-Donne, I., R. Rossi, D. Giustarini, N. Gagliano, L. Lusini, A. Milzani, P. Di Simplicio, and R. Colombo. 2001. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic. Biol. Med. 1: 1075-1083. (Pubitemid 33000129)
17. Kuo, C. F., and I. Fridovitc. 1986. Free-radical chain oxidation of 2-nitropropane initiated and propagated by superoxide. Biochem. J. 237: 505-510.
18. Sakai, T., T. Ishizaki, T. Nakai, S. Miyabo, S. Matsukawa, M. Hayakawa, and T. Ozawa. 1996. Role of nitric oxide and superoxide anion in leukotoxin-,9,10-epoxy-12-octadecenoate-induced mitochondrial dysfunction. Free Radic. Biol. Med. 20: 607-612. (Pubitemid 126350066)
19. Beckman, J. S., T. W. Beckman, J. Chen, P. A. Marshall, and B. A. Freeman. 1990. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87: 1620-1624. (Pubitemid 20080360)
20. Hughes, M. N., and H. G. Nicklin. 1968. The chemistry of pernitrite: Part 1. Kinetics of decomposition of pernitrous acid. J. Am. Chem. Soc. 2: 450-452.
21. Walling, C. 1982. The nature of the primary oxidants in oxidations mediated by metal ions. In Oxidases and Related Redox Systems. T. E. King, H. S. Mason, and M. Morrison, eds. Pergamon Press, Oxford, U.K., p. 85-97.
22. Norisue, M., K. Todoki, and E. Okabe. 1997. Inhibition by hydroxyl radicals of calcitonin gene-related peptide-mediated neurogenic vasorelaxation in isolated canine lingual artery. J. Pharmacol. Exp. Ther. 280: 492-500. (Pubitemid 27171439)
23. Burdick, M. D., L. A. Murray, M. P. Keane, Y. Y. Xue, D. A. Zisman, J. A. Belperio, and R. M. Strieter. 2005. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. 171: 261-268.
24. Preud'homme, J. L., E. Rochard, D. Gouet, F. Danon, M. Alcalay, G. Touchard, and P. Aucouturier. 1988. Isotypic distribution of anti-double-stranded DNA antibodies: a diagnostic evaluation by enzyme-linked immunosorbent assay. Diagn. Clin. Immunol. 5: 256-261.
25. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475-1489.
26. Nobrega, A., M. Haury, A. Grandien, E. Malanchere, A. Sundblad, and A. Coutinho. 1993. Global analysis of antibody repertoires. II. Evidence for specificity, self-selection and the immunological "homunculus" of antibodies in normal serum. Eur. J. Immunol. 23: 2851-2859.
27. Witko-Sarsat, V., M. Friedlander, C. Capeillere-Blandin, T. Nguyen-Khoa, A. T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49: 1304-1313. (Pubitemid 26166404)
28. Holden, J. A., D. H. Rolfson, and R. H. Low. 1990. DNA topoisomerase I from placenta. Biochim. Biophys. Acta 1049: 303-310.
29. Min, L. J., T. X. Cui, Y. Yahata, K. Yamasaki, T. Shiuchi, H. W. Liu, R. Chen, J. M. Li, M. Okumura, T. Jinno, et al. 2004. Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes. Endocrinology 145: 253-260.
30. Casciola-Rosen, L., F. Wigley, and A. Rosen. 1997. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J. Exp. Med. 185: 71-79. (Pubitemid 27039442)
31. Witko-Sarsat, V., M. Friedlander, T. Nguyen Khoa, C. Capeillere-Blandin, A. T. Nguyen, S. Canteloup, J. M. Dayer, P. Jungers, T. Drüeke, and B. Descamps-Latscha. 1998. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161: 2524-2532. (Pubitemid 28397070)
32. Alderman, C. J., S. Shah, J. C. Foreman, B. M. Chain, and D. R. Katz. 2002. The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic. Biol. Med. 1: 377-385.
33. Li, H. Y., F. F. Hou, X. Zhang, P. Y. Chen, S. X. Liu, J. X. Feng, Z. Q. Liu, Y. X. Shan, G. B. Wang, Z. M. Zhou, et al. 2007. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J. Am. Soc. Nephrol. 18: 528-538.
34. Ho, K. T., and J. D. Reveille. 2003. The clinical relevance of autoantibodies in scleroderma. Arthritis Res. Ther. 5: 80-93.
35. Kahaleh, M. B., and E. C. LeRoy. 1999. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity. 31: 195-214. (Pubitemid 30179202)
36. Chizzolini, C., Y. Parel, C. De Luca, A. Tyndall, A. Akesson, A. Scheja, and J. Dayer. 2003. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated-tumor necrosis factor α. Arthritis Rheum. 48: 2593-2604. (Pubitemid 37129436)
37. Matsushita, T., M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara, and S. Sato. 2005. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54: 192-201. (Pubitemid 43122202)
38. + T cells from scleroderma patients. Arthritis Rheum. 48: 2262-2274.
39. Snider, G. L., J. A. Hayes, and A. L. Korthy. 1978. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: pathology and stereology. Am. Rev. Respir. Dis. 117: 1099-1108.
40. Yamamoto, T., S. Takagawa, I. Katayama, K. Yamazaki, Y. Hamazaki, H. Shinkai, and K. Nishioka. 1999. Animal model of sclerotic skin: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J. Invest. Dermatol. 112: 456-462. (Pubitemid 29171935)
41. Yoshizaki, A., Y. Iwata, K. Komura, F. Ogawa, T. Hara, E. Muroi, M. Takenaka, K. Shimizu, M. Hasegawa, M. Fujimoto, T. Tedder, and S. Sato. 2008. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am. J. Pathol. 172: 1650-1663. (Pubitemid 351793356)
42. Oi, M., T. Yamamoto, and K. Nishioka. 2004. Increased expression of TGF-β1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J. Med. Dent. Sci. 51: 7-17. (Pubitemid 41114818)
43. Cotton, S. A., A. L. Herrick, M. I. Jayson, and A. J. Freemont. 1998. TGF β: a role in systemic sclerosis? J. Pathol. 184: 4-6.
44. Querfeld, C., B. Eckes, C. Huerkamp, T. Krieg, and S. Sollberg. 1999. Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma. J. Dermatol. Sci. 21: 13-22. (Pubitemid 29347106)
45. Needleman, B. W., J. Choi, A. Burrows-Mezu, and J. A. Fontana. 1990. Secretion and binding of transforming growth factor β by scleroderma and normal dermal fibroblasts. Arthritis Rheum. 33: 650-656. (Pubitemid 20166566)